SAP partners with Snowflake to enhance enterprise AI capabilities through integrated cloud solutions

Christian Klein Chief Executive Officer (CEO) SAP SE
Christian Klein Chief Executive Officer (CEO) - SAP SE
0Comments

Snowflake and SAP SE have announced a new partnership to integrate Snowflake’s AI Data Cloud with the SAP Business Data Cloud (SAP BDC). This collaboration aims to provide organizations with access to semantically rich data, supporting the development of artificial intelligence applications that can help accelerate business outcomes.

The companies will offer a new solution called SAP Snowflake, which will be available as an extension for SAP BDC customers. This product combines SAP’s expertise in business processes and data management with Snowflake’s platform for building AI and machine learning solutions. The integration also includes zero-copy sharing between SAP BDC and Snowflake, allowing customers to share data across platforms without duplication.

Christian Kleinerman, Executive Vice President of Product at Snowflake, said: “By tightly integrating SAP and Snowflake, we’re making it simple for enterprises to connect their critical business data with its rich context in SAP with the power of seamless AI app and data agent development at scale in Snowflake. Enterprises can now innovate faster with Snowflake and SAP BDC and seamlessly share data between the platforms—zero-copy and fully governed.”

With this integration, customers are expected to benefit from more openness and choice when working within the SAP ecosystem. They can use both systems together for cloud-scale computing, storage options, analytics, marketplace access, and collaborative features. The partnership enables bidirectional zero-copy access so teams can work on real-time data within a unified governance framework.

Irfan Khan, President and Chief Product Officer for SAP Data and Analytics at SAP SE, commented: “Bringing Snowflake to SAP Business Data Cloud empowers our customers with openness and choice. Together, we combine SAP’s decades of leadership in mission-critical business applications with Snowflake’s modern data platform to deliver a unified, enterprise-ready, and SAP-supported experience that extends the value of business data across the entire ecosystem.”

The new offering is designed to help organizations unify their data landscape by integrating both SAP and non-SAP sources. It supports advanced modeling capabilities for analytics as well as machine learning workflows across enterprises. The system also simplifies AI governance while helping build intelligent applications grounded in trusted business information.

AstraZeneca is among several large organizations already using solutions from both companies. Russell Smith, Vice President of ERP Transformation Technology at AstraZeneca stated: “AstraZeneca is constantly pushing the boundaries of science and is pioneering in life-changing medicines. Data and AI are central to achieving this aim, and our close collaboration with SAP and Snowflake compliments our ability to access, process and analyze real-time data. This announcement will accelerate our mission and recognizes that every minute matters to make breakthroughs for patients.”

In addition to the main solution extension (SAP Snowflake), there will be an additional capability called SAP Business Data Cloud Connect for Snowflake enabling further integration through bidirectional zero-copy sharing.

SAP plans general availability of these offerings beginning in Q1 2026 for the main solution extension (SAP Snowflake) while BDC Connect for Snowflake is planned for H1 2026.

For more information about these products or partnership details:
– Visit www.sap.com
– Learn more about the power of SAP Business Data Cloud
– See partner updates on the official partner page or Snowflake’s blog
– Follow announcements on LinkedIn or X

###



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.